Gastrointestinal Oncology: A Critical Multidisciplinary Team Approach > Gastroenterology

This is the first evidence-based reference text written for the multidisciplinary team of medical professionals involved in the investigation, diagnosis and management of patients with gastrointestinal cancer.
Written by the leading international experts in the field, it sets the standard in clinical practice. It contains specially structured clinical chapters each representing a different role in the MDT - which enables clear presentation and quick reference of the contents

List of Contributors.
Preface.
Foreword.
Part I: Gastroesophageal Cancer (Edited by Richard Sampliner, University of Arizona College of Medicine).
1 Epidemiology of Gastroesophageal Cancer (Evan S. Dellon, University of North Carolina School of Medicine and Nicholas J. Shaheen, University of North Carolina School of Medicine).
2 Factors involved in Carcinogenesis and Prevention (Mark R. Anderson, City Hospital, Birmingham and Janusz Jankowski, University of Oxford).
3 Molecular Biology of Gastroesophageal Cancers: The Role of Mutational Analysis in Prognosis (Matthew Lovell, St Bartholomew’s and the London School of Medicine and Dentistry; Chetan Bhan, Eastbourne Hospital; Janusz Jankowski and Stuart McDonald, University of Oxford).
4 Esophageal Adenocarcinoma (Edited by Kenneth K. Wang, Department of Gastroenterology and Hepatology, Rochester, USA).
Diagnosis.
Endoscopic diagnosis of Barrett’s esophagus (Vidu B. Mokkala, Mayo Clinic, Rochester, USA; Navtej S. Buttar, Mayo Clinic, Rochester, USA; and Louis M. Wong Kee Song, Mayo Clinic, Rochester, USA).
The histologic diagnosis of Barrett’s esophagus (Thomas C. Smyrk, Mayo Clinic, Rochester, USA and Navtej S. Buttar, Mayo Clinic, Rochester, USA).
Staging of esophageal cancer (Ananya Das, Mayo Clinic Arizona and Amitabh Chak, Case Western Reserve University School of Medicine).
Treatment.
Overview (Kenneth K. Wang, Mayo Clinic, Rochester, USA).
Surgical management of esophageal carcinoma (Daniela Molena, University of Rochester Medical Center, USA; Fernando Herbella, University of Rochester, USA; and Jeffrey H. Peters, University of Rochester, USA).
Chemotherapy for metastatic cancer of the esophagus, gastroesophageal junction, and stomach (Aminah Jatoi, Mayo Clinic, Rochester, USA).
Concurrent radiochemotherapy for esophageal cancer: Zhongxing Liao (The University of Texas M. D. Anderson Cancer Center), Luka Milas (The University of Texas M. D. Anderson Cancer Center), Ritsuko Komaki (Anderson Cancer Center, Houston) & Jaffer Ajani (University of Texas MD Anderson Cancer Center).
Ablation, novel agents, and endoscopic therapy for esophageal dysplasia and carcinoma: Herbert C. Wolfsen (Mayo Clinic College of Medicine, Rochester, USA).
Prognosis and follow-up: Kenneth K. Wang (Mayo Clinic, Rochester, USA).
5 Squamous Cancer of the Esophagus: Edited by Hugh Barr (Gloucestershire Royal Hospital).
Diagnosis.
History and etiology: Alastair Sammon (Gloucestershire Hospitals NHS Foundation Trust) & Mark Vipond (Gloucestershire Royal NHS Foundation Trust).
Clinical: Alastair Sammon (Gloucestershire Hospitals NHS Foundation Trust) & Mark Vipond (Gloucestershire Royal NHS Foundation Trust).
Histopathology and staging: Salim Anjarwalla (Gloucestershire Royal Hospital), David Hewin (Gloucestershire Royal Hospital) & Neil A. Shepherd (Gloucestershire Royal Hospital).
Imaging and clinical staging: David Hewin (Gloucestershire Royal Hospital), Neil A. Shepherd (Gloucestershire Royal Hospital) & Salim Anjarwalla (Gloucestershire Royal Hospital).
Treatment.
Overview: Hugh Barr (Gloucestershire Royal Hospital).
Surgery: Ferdinandos Skoulidis (University of Cambridge), Yu Jo Chua (Royal Marsden Hospital, Surrey) & David Cunningham (John Radcliffe Hospital, Oxford).
Chemotherapy: Ferdinandos Skoulidis (University of Cambridge), Yu Jo Chua (Royal Marsden Hospital, Surrey) & David Cunningham (John Radcliffe Hospital, Oxford).
Radiotherapy: Ferdinandos Skoulidis (University of Cambridge), Yu Jo Chua (Royal Marsden Hospital, Surrey) & David Cunningham (John Radcliffe Hospital, Oxford).
Ablation of early cancer: Hugh Barr (Gloucestershire Royal Hospital).
Palliation and endoscopic therapy: Hugh Barr (Gloucestershire Royal Hospital).
Novel agents: Ferdinandos Skoulidis (University of Cambridge), Yu Jo Chua (Royal Marsden Hospital, Surrey) & David Cunningham (Royal Marsden Hospital, Surrey).
Prognosis and follow-up: Hugh Barr (Gloucestershire Royal Hospital).
6 Diffuse Gastric Cancer: Edited by Ilfet Songun (Leiden University Medical Center) & Cornelius van de Velde (Leiden University Medical Center).
Diagnosis.
History: Ilfet Songun (Leiden University Medical Center) & Cornelius van de Velde (Leiden University Medical Center).
Clinical: Annemieke Cats (Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital).
Histopathology and molecular pathology: Cen Si (Vrije Universiteit Medical Center, Amsterdam), Nicole C.T. van Grieken (Vrije Universiteit Medical Center, Amsterdam) & Gerrit A. Meijer (Vrije Universiteit Medical Center, Amsterdam).
Imaging and staging of gastric cancer: Regina G.H. Beets-Tan (University Hospital Maastrict) & Cornelius van de Velde (Leiden University Medical Center).
Treatment.
Overview: Ilfet Songun (Leiden University Medical Center) & Cornelius van de Velde (Leiden University Medical Center).
Surgery: Ilfet Songun (Leiden University Medical Center) & Cornelius van de Velde (Leiden University Medical Center).
Chemotherapy: Christopher Jackson (Royal Marsden Hospital, Surrey), Naureen Starling (Royal Marsden Hospital, Surrey) & David Cunningham (Royal Marsden Hospital, Surrey).
Radiotherapy: Edwin P.M. Jansen (The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital) & Marcel Verheij (The Netherlands Cancer Institute/ Antoni van Leeuwenhoek Hospital).
Novel agents: Annemieke Cats (Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital).
Prognosis and follow-up: Ilfet Songun (Leiden University Medical Center) & Cornelius van de Velde (Leiden University Medical Center).
7 Intestinal Gastric Cancer: Edited by Benjamin C.Y. Wong (University of Hong Kong).
Diagnosis: history, clinical and histopathology: Annie O. O. Chan (Queen Mary Hospital, Hong Kong) & Asif Rashid (MD Anderson Cancer Center, Houston).
Imaging and staging: Annie O.O. Chan (Queen Mary Hospital, Hong Kong) & Benjamin C.Y. Wong (University of Hong Kong).
Treatment: Annie O.O. Chan (Queen Mary Hospital, Hong Kong) & Benjamin C.Y. Wong (University of Hong Kong).
Prognosis and follow-up: Annie O.O. Chan (Queen Mary Hospital, Hong Kong) & Benjamin C.Y. Wong (University of Hong Kong).
8 Small Bowel Tumors: Edited by Nadir Arber (Tel Aviv Medical Center and Tel Aviv University).
Diagnosis.
Epidemiology: Kerin Adelson (Mount Sinai School of Medicine, New York), Eyal Sagiv (Tel Aviv Medical Center), Nadir Arber (Tel Aviv Medical Center and Tel Aviv University) & Alfred I. Neugut (Columbia University Medical Center, New York).
Endoscopy in the diagnosis of small bowel tumors: Ian M. Gralnek (Rambam Health Care Campus, Israel) & Rami Eliakim (Technion-Israe Institute of Technology, Israel).
Molecular biology of small bowel tumors: Eyal Sagiv (Tel Aviv Medical Center), Kerin Adelson (Mount Sinai School of Medicine, New York), Alfred I. Neugut (Columbia University Medical Center, New York) & Nadir Arber (Tel Aviv Medical Center and Tel Aviv University).
Imaging and staging: Yulia Bronstein (MD Anderson Cancer Center, Houston) & Ronelle Dubrow (MD Anderson Cancer Center, Houston).
Treatment.
Surgery: Ido Nachmany (Tel Aviv University) & Joseph M. Klausner (Tel Aviv University).
Other treatments: Pascal Peeters (University Hospital Gasthuisberg, Belgium), Eric Van Cutsem (University Hospital Gasthuisberg, Belgium) & Mario Dicato (Luxembourg Medical Center).
9 Sarcoma and Gastrointestinal Stromal Tumors: Edited by Markku Miettinen (Armed Forces Institute of Pathology, Washington).
Introduction: Markku Miettinen (Armed Forces Institute of Pathology, Washington).
Pathology, prognosis and genetics of gastrointestinal stromal tumors (GISTs): Markku Miettinen (Armed Forces Institute of Pathology, Washington) & Jerzy Lasota (Armed Forces Institute of Pathology, Washington).
Imaging and staging of gastrointestinal stromal tumors: Angela D. Levy (Uniformed Services University of the Health Sciences, Maryland).
Treatment: Heikki Joensuu (Helsinki University Central Hospital) & Ronald P. DeMatteo (Memorial Sloan-Kettering Cancer Center, New York).
10 Rare Tumors of the Abdomen: Edited by Anil R. Prasad (University of Arizona Health Sciences Center).
Smooth muscle and pericytic tumors: Mitual Amin (William Beaumont Hospital, USA), Malathy Kapali (University of Arizona), Benjamin Paz (City of Hope National Medical Center, California), Sanjay Saluja (Yale University School of Medicine) & Tomislav Dragovich (Arizona Cancer Center /University Medical Center).
Vascular tumors: Mitual Amin (William Beaumont Hospital, USA), Malathy Kapali (University of Arizona), Benjamin Paz (City of Hope National Medical Center, California), John Fetsch (Armed Forces Institute of Pathology, Washington) & Tomislav Dragovich (Arizona Cancer Center /University Medical Center).
Adipose tissue tumors: John Fetsch (Armed Forces Institute of Pathology, Washington), Anil R. Prasad (University of Arizona Health Sciences Center), Sanjay Saluja (Yale University School of Medicine) & Benjamin Paz (City of Hope National Medical Center, California).
Neurogenic tumors: Anil R. Prasad (University of Arizona Health Sciences Center), Markku Miettenen (Armed Forces Institute of Pathology, Washington) & Benjamin Paz (City of Hope National Medical Center, California).
Myofibroblastic and fi brous tumors: John Fetsch (Armed Forces Institute of Pathology, Washington), Malathy Kapali (University of Arizona), Benjamin Paz (City of Hope National Medical Center, California), Sanjay Saluja (Yale University School of Medicine) & Tomislav Dragovich (Arizona Cancer Center /University Medical Center).
Mesothelial tumors: Anil R. Prasad (University of Arizona Health Sciences Center), Malathy Kapali (University of Arizona), Sanjay Saluja (Yale University School of Medicine) & Tomislav Dragovich (Arizona Cancer Center /University Medical Center).
Gastric lymphomas: Anil R. Prasad (University of Arizona Health Sciences Center), Sanjay Saluja (Yale University School of Medicine) & Daniel O. Persky (University of Arizona Health Sciences Center).
Rare miscellaneous tumors and tumor-like lesions: Anil R. Prasad (University of Arizona Health Sciences Center), John Fetsch (Armed Forces Institute of Pathology, Washington), Sanjay Saluja (Yale University School of Medicine) & Tomislav Dragovich (Arizona Cancer Center /University Medical Center).
Part II: Colorectal Cancer (Edited by David Kerr, University of Oxford).
11 Epidemiology and Prevention of Colorectal Cancer: Paul Moayyedi (McMaster University Medical Centre, Canada).
12 The Molecular Pathology of Sporadic and Hereditary Colorectal Cancer: Massimo Pignatelli (Bristol Royal Infirmary), Nahida Banu (Bristol Royal Infirmary) & Zsombor Melegh (Bristol Royal Infirmary).
13 Screening for Colorectal Cancer: Robert J.C. Steele (Ninewells Hospital and Medical School, Dundee).
14 Cancer of the Colon and Rectum: Edited by Rachel S. Midgley (University of Oxford).
Diagnosis.
Clinical presentation: Omar Khan (Churchill Hospital, Oxford), Rachel S. Midgley (University of Oxford) & Andrew Weaver (John Radcliffe Hospital, Oxford).
Histopathology: Daniel Royston (John Radcliffe Hospital, Oxford) & Bryan Warren (John Radcliffe Hospital, Oxford).
Imaging and staging: Margaret Betts (John Radcliffe Hospital, Oxford).
Treatment.
Overview of therapy modalities: Rachel S. Midgley (University of Oxford).
Surgery: Baljit Singh (John Radcliffe Hospital, Oxford) & Chris Cunningham (John Radcliffe Hospital, Oxford).
Chemotherapy: Ami Sabharwal (University of Oxford) & David Kerr (University of Oxford).
Radiotherapy for rectal cancer: Robert Glynne-Jones (Mount Vernon Cancer Centre).
Surgery for liver metastases: Zahir Soonwalla (John Radcliffe Hospital, Oxford).
Ablative treatments: Fergus Gleeson (The Churchill Hospital, Oxford).
Novel therapies: Carlos Escriu (Clatterbridge Centre for Oncology, Liverpool), Mark Middleton (Churchill Hospital, Oxford) & Rachel S. Midgley (University of Oxford).
Stomas: Ann MacArthur (Oxford Radcliffe Hospitals NHS Trust) & Julia Liddi (John Radcliffe Hospital, Oxford).
Answers to case scenerios: Omar Khan (Churchill Hospital, Oxford), Rachel S. Midgley (University of Oxford) & Andrew Weaver (John Radcliffe Hospital, Oxford).
15 Rare Cancers: Edited by Colin McArdle (Royal Infirmary, Glasgow).
Gastrointestinal carcinoids: Irwin M. Modlin (Yale University School of Medicine), Jon Bornschein (Yale University School of Medicine) & Mark Kidd (Yale University School of Medicine).
Anorectal melanoma: Gary N. Mann (University of Washington Medical Center), Shailender Bhatia (University of Washington) & John L. Thompson (University of Washington).
Cancer of the anal canal: Matthew Clark (University of Auckland) & Lincoln Israel (Middlemore Hospital, Auckland).
Appendiceal epithelial neoplasms: Paul H. Sugarbaker (Washington Hospital Center).
Diffuse malignant peritoneal mesothelioma: Tristan D. Yan (Washington Hospital Center) & Paul H. Sugarbaker (Washington Hospital Center).
Part III: Hepatobiliary Cancer (Edited by Yuman Fong, Memorial Sloan-Kettering Cancer Center, New York).
16 Epidemiology of Hepatocellular Carcinoma: Hashem B. El-Serag (College of Medicine, Houston), Donna L. White (Baylor College of Medicine, Houston) & Zhannat Nurgalieva (Baylor College of Medicine, Houston).
17 Factors involved in Carcinogenesis and Prevention in Hepatobiliary Cancer: Paula Ghaneh (University of Liverpool), William Greenhalf (University of Liverpool) & John P. Neoptolemos (University of Liverpool).
18 Molecular Biology of Hepatobiliary Cancer: Knut Ketterer (Technical University of Munich) & Helmut Friess (Technical University of Munich).
19 Primary Liver Cancer: Edited by Charlie Pan (University of Michigan Medical School) & Theodore Lawrence (University of Michigan).
Diagnosis.
History and clinical: Jorge A. Marrerro (University of Michigan) & Charlie Pan (University of Michigan Medical School).
Histopathology: Rebecca F. Harrison (Leicester General Hospital) & Angus H. McGregor (Leicester Royal Infirmary).
Imaging and staging: Jonathon Willatt (University of Michigan) & Hero K. Hussain (University of Michigan Health System).
Treatment.
Overview: Charlie Pan (University of Michigan Medical School).
Surgery: Shawn J. Pelletier (University of Michigan Health System) & James A. Knol (University of Michigan Department of Surgery).
Ablation: James A. Knol (University of Michigan Department of Surgery).
Radiotherapy: Charlie Pan (University of Michigan Medical School) & Theodore Lawrence (University of Michigan).
Chemotherapy: Charlie Pan (University of Michigan Medical School) & William D. Ensminger (Upjohn Center SPC 5504, USA).
Novel agents: Charlie Pan (University of Michigan Medical School) & William D. Ensminger (Upjohn Center SPC 5504, USA).
Prognosis and follow-up: Charlie Pan (University of Michigan Medical School).
20 Metastatic Liver Cancer: Edited by Yuman Fong (Memorial Sloan-Kettering Cancer Center, New York).
Treatment.
Overview: Yuman Fong (Memorial Sloan-Kettering Cancer Center, New York).
Surgical therapy for hepatic colorectal metastases: Darren Carpizo (Memorial Sloan-Kettering Cancer Center, New York) & Yuman Fong (Memorial Sloan-Kettering Cancer Center, New York).
Systemic chemotherapy: Nancy Kemeny (Memorial Sloan-Kettering Cancer Center, New York).
Ablative Therapy: Anne M. Covey (Memorial Sloan-Kettering Cancer Center, New York).
Radiation therapy: Christopher Willet (Duke University Medical Center, USA) & Brian G. Czito (Duke University Medical Center, USA).
21 Primary Pancreatic Adenocarcinoma: Edited by Christopher L. Wolfgang (Johns Hopkins Hospital, USA).
Diagnosis.
Epidemiology, history and clinical fi ndings: Timothy M. Pawlik (Johns Hopkins School of Medicine, USA).
Histopathology: Ralph H. Hruban (The Johns Hopkins Medical Institutions, USA).
CT imaging in pancreatic cancer: Karen M. Horton (Johns Hopkins Medical Institutions, USA) & Elliot K. Fishman (Johns Hopkins Hospital, USA).
Treatment.
Overview: Christopher L. Wolfgang (Johns Hopkins Hospital, USA).
Surgery: Robert A. Meguid (Johns Hopkins University School of Medicine, USA) & Christopher L. Wolfgang (Johns Hopkins Hospital, USA).
Chemotherapy: Daniel Laheru (The Johns Hopkins University School of Medicine, USA).
Radiotherapy: Joseph Herman (The Johns Hopkins University, USA).
Novel agents: Manuel Hildago (The Johns Hopkins University School of Medicine, USA).
Prognosis and follow-up: Jeffrey Infante (Sarah Cannon Research Institute, USA) & Wells Messersmith (University of Colorado).
22 Cholangiocarcinoma: Edited by Ravi S. Chari (Vanderbilt University Medical Center, USA).
Diagnosis.
Overview: Ravi S. Chari (Vanderbilt University Medical Center, USA).
History: T. Markley Earl (Vanderbilt University School of Medicine, USA), Burnett S. Kelly (Vanderbilt University Medical Center, USA) & Ravi S. Chari (Vanderbilt University Medical Center, USA).
Clinical: T. Markley Earl (Vanderbilt University School of Medicine, USA), Burnett S. Kelly (Vanderbilt University Medical Center, USA) & Ravi S. Chari (Vanderbilt University Medical Center, USA).
Histopathology: Elizabeth I. Johnston (Vanderbilt University School of Medicine, USA) & Mary Kay Washington (Vanderbilt University Medical Center, USA).
Imaging and Staging: Christopher D. Anderson (Washington University in St. Louis), T. Markley Earl (Vanderbilt University School of Medicine, USA), Stephen J. Meranze (Vanderbilt University Medical Center, USA) & Ravi S. Chari (Vanderbilt University Medical Center, USA).
Treatment.
Overview: Ravi S.Chari (Vanderbilt University Medical Center, USA).
Surgery: Christopher D. Anderson (Washington University in St. Louis) & Ravi S. Chari (Vanderbilt University Medical Center, USA).
Chemotherapy: Laura A. Williams (Vanderbilt University, USA) & Jordan Berlin (Vanderbilt University, USA).
Role of radiation therapy: Jayamarx Jayaraman (Vanderbilt University Medical Center, USA) & A. Bapsi Chakravarthy (Vanderbilt University Medical Center, USA).
Ablation: Christopher D. Anderson (Washington University in St. Louis) & Ravi S. Chari (Vanderbilt University Medical Center, USA).
Prognosis and follow-up: Christopher D. Anderson (Washington University in St. Louis) & Ravi S. Chari (Vanderbilt University Medical Center, USA).
23 Neuroendocrine Tumors: Edited by Ursula Plöckinger (Charité-Universitätsmedizin Berlin).
History and histopathology: Guido Rindi (University of Parma) & Cesare Bordi (Universita Degli Studi di Parma).
Diagnosis, staging, prognosis and follow-up:.
Gastric neuroendocrine tumors: Gianfranco Delle Fave (Università di Roma ‘La Sapienza’).
Gastrinoma: Frédérique Maire (Hôpital Beaujon, Clichy) & Phillippe Ruszniewski (Université Denis Diderot, Paris).
Insulinoma: Wouter W. de Herder (Erasmus MC, Rotterdam).
Non-functioning endocrine tumors of the pancreas: Dimitios Papdogias (General Hospital ‘G. Gennimatas’, Athens) & Gregory Kaltsas (National University of Athens).
Rare functioning pancreatic endocrine tumors: Dermot O’Toole (St James’s Hospital and Trinity College Dublin).
Midgut and appendiceal tumors: Barbro Eriksson (Uppsala University Hospital).
Neuroendocrine tumors of the colon and rectum: Christoph J. Auernhammer (Klinikum der Ludwig-Maximilians-Universität, München).
Imaging of gastroenteropancreatic neuroendocrine tumors: Anders Sundin (Karolinska University Hospital Solna, Stockholm).
Treatment.
Overview: Rudolf Arnold (University, Marburg) & Anja Rinke (Philipps Universität Marburg).
Surgery: pancreatic tumors: Göran Åkerström (University Hospital, Uppsala) & Per Hellman (University Hospital, Uppsala).
Surgery: midgut tumors: Matthias Rothmund (Philipps Universität Marburg).
Surgery: liver metastases: Håkan Ahlman (University of Göteborg, Sweden) & Michael Olausson (University of Göteborg, Sweden).
Ablative therapy: Massimo Falconi (Policlinico ‘GB Rossi’, Veroni) & Rossella Bettini (Gastroenterologiche Policlinico ‘GB Rossi’, Verona).
Radiolabeled somatostatin analogs: Dik J. Kwekkeboom (University Hospital Rotterdam), Jaap J.M. Teunissen (University Hospital Rotterdam), Boen L. Kam (Erasmus MC, Rotterdam), Roelf Valkema (Erasmus MC, Rotterdam), Wouter W. de Herder (Erasmus MC, Rotterdam) & Eric P. Krenning (Erasmus MC, Rotterdam).
Biotherapy and chemotherapy: Ursula Plöckinger (Charité-Universitätsmedizin Berlin).
Novel agents: Marianne Pavel (Universitätsklinikum Ulmenweg, Erlangen).
24 Rare Tumors of the Liver: Shantanu Battacharjya (BGS Global Hospital, Bangalore), Zahir Soonawalla (John Radcliffe Hospital), Rachel R. Phillips (University of Oxford) & Peter J. Friend (University of Oxford).
25 Cystic Neoplasms of the Pancreas: Edited by Peter J. Allen (Memorial Sloan-Kettering Cancer Center, New York).
Diagnosis and imaging: John Mansour (Memorial Sloan-Kettering Cancer Center, New York) & Lawrence Schwartz (Memorial Sloan-Kettering Cancer Center, New York).
Treatment recommendations: John Mansour (Memorial Sloan-Kettering Cancer Center, New York) & Peter J. Allen (Memorial Sloan-Kettering Cancer Center, New York).
Endoscopic assessment and treatment: Mark Greaves (Memorial Sloan-Kettering Cancer Center, New York) & Mark Schattner (Memorial Sloan-Kettering Cancer Center, New York).
Index.

등록된 상품문의

상품문의 쓰기 새 창 더보기

상품문의가 없습니다.